LU91083I9 - - Google Patents

Info

Publication number
LU91083I9
LU91083I9 LU91083C LU91083C LU91083I9 LU 91083 I9 LU91083 I9 LU 91083I9 LU 91083 C LU91083 C LU 91083C LU 91083 C LU91083 C LU 91083C LU 91083 I9 LU91083 I9 LU 91083I9
Authority
LU
Luxembourg
Prior art keywords
synthesis
disclosed
acid compounds
boronic ester
novel boronic
Prior art date
Application number
LU91083C
Other languages
English (en)
Other versions
LU91083I2 (fr
Inventor
Julian Adams
Yu-Ting Ma
Ross Stein
Matthew Baevsky
Louis Grenier
Louis Plamondon
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26987313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91083(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of LU91083I2 publication Critical patent/LU91083I2/fr
Publication of LU91083I9 publication Critical patent/LU91083I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU91083C 1994-10-28 2004-06-09 Bortezomib ou un des ester pharmaceutiquement acceptables, optionnellement sous forme d'un sel pharmaceutiquement acceptable-Velcade. LU91083I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33052594A 1994-10-28 1994-10-28
US08/442,581 US6083903A (en) 1994-10-28 1995-05-16 Boronic ester and acid compounds, synthesis and uses
PCT/US1995/014117 WO1996013266A1 (fr) 1994-10-28 1995-10-27 Composes d'esters et d'acides boroniques, leur synthese et leurs utilisations

Publications (2)

Publication Number Publication Date
LU91083I2 LU91083I2 (fr) 2004-08-09
LU91083I9 true LU91083I9 (fr) 2018-12-28

Family

ID=26987313

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91083C LU91083I2 (fr) 1994-10-28 2004-06-09 Bortezomib ou un des ester pharmaceutiquement acceptables, optionnellement sous forme d'un sel pharmaceutiquement acceptable-Velcade.

Country Status (25)

Country Link
US (16) US6083903A (fr)
EP (4) EP1627880B1 (fr)
JP (1) JP3717934B2 (fr)
KR (1) KR100398944B1 (fr)
CN (2) CN1305475C (fr)
AT (3) ATE411324T1 (fr)
AU (1) AU710564B2 (fr)
CA (2) CA2496538C (fr)
CH (1) CH0788360H1 (fr)
CY (1) CY2484B1 (fr)
DE (5) DE69535866D1 (fr)
DK (3) DK1312609T3 (fr)
ES (3) ES2254803T3 (fr)
FI (2) FI114801B (fr)
FR (1) FR04C0014I2 (fr)
HK (2) HK1002059A1 (fr)
IL (5) IL133831A (fr)
LU (1) LU91083I2 (fr)
MX (1) MX9703063A (fr)
NL (1) NL300151I2 (fr)
NO (2) NO310558B1 (fr)
NZ (2) NZ337211A (fr)
PT (3) PT1627880E (fr)
TW (1) TW318850B (fr)
WO (1) WO1996013266A1 (fr)

Families Citing this family (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
FR2758329B1 (fr) * 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
NZ337364A (en) * 1997-02-15 2001-06-29 Millennium Pharm Inc Treatment of infarcts, ischemia and reperfusion through inhibition of NFkappaB
US6221888B1 (en) * 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
EP1017398A1 (fr) * 1997-09-25 2000-07-12 Proscript, Inc. INIHIBITEURS DE PROTEASOME, INHIBITEURS DES VOIES DE L'UBIQUITINE OU AGENTS ENTRAVANT L'ACTIVATION DE NF-$g(k)B PAR LES VOIES DE l'UBIQUITINE PROTEASOME POUR TRAITER DES MALADIES INFLAMMATOIRES ET DES MALADIES AUTOIMMUNES
TR200000815T2 (tr) * 1997-09-29 2000-12-21 Point Therapeutics Inc. In vitro hematopoietik hücrelerin stimulasyonu.
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
CA2219867A1 (fr) * 1997-10-31 1999-04-30 Jiangping Wu Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique
DE19802450A1 (de) * 1998-01-23 1999-07-29 Hoechst Marion Roussel De Gmbh Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
EP0982317A1 (fr) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs bivalents de protéasome
BR9914648A (pt) * 1998-10-20 2001-11-27 Millennium Pharm Inc Processo para monitorar ação medicamentosa deinibidor de proteasoma
US6492333B1 (en) * 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6649593B1 (en) * 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
AU2001287399A1 (en) * 2000-08-16 2002-02-25 University Of Alberta Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
US6919382B2 (en) 2000-08-31 2005-07-19 The Governors Of The University Of Alberta Preparation and uses of conjugated solid supports for boronic acids
CA2425632A1 (fr) * 2000-10-12 2002-04-18 Viromics Gmbh Moyens pour le traitement d'infections a des virus
EP1355910B1 (fr) * 2001-01-25 2011-03-09 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation de composes d'acide boronique
CA2447909C (fr) 2001-05-21 2011-04-05 Alcon, Inc. Utilisation d'inhibiteurs de proteasome pour traiter des secheresses de l'oeil
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6933290B2 (en) 2001-05-30 2005-08-23 Novartis Ag 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
WO2003033507A1 (fr) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
AU2003218232A1 (en) * 2002-03-12 2003-09-29 Ariad Pharmaceuticals, Inc. Peptide analogues and uses thereof
ATE396971T1 (de) 2002-03-13 2008-06-15 Janssen Pharmaceutica Nv Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
WO2003075929A1 (fr) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Inhibiteurs de l'histone déacétylase
WO2003076438A1 (fr) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Derives piperazinyl-, piperidinyl- et morpholinyl- utilises en tant que nouveaux inhibiteurs d'histone deacetylase
PL205531B1 (pl) 2002-03-13 2010-04-30 Janssen Pharmaceutica Nv Pochodna karbonyloaminowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
DE10316735A1 (de) * 2002-04-05 2003-11-20 Viromics Gmbh Mittel zur Behandlung von Flaviviridae-Infektionen
WO2003106384A2 (fr) * 2002-06-01 2003-12-24 Johns Hopkins University Nouveaux derives de chalcone borique et utilisations correspondantes
AU2003265264A1 (en) * 2002-07-09 2004-01-23 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds
DK1536777T3 (da) * 2002-08-14 2007-06-04 Janssen Pharmaceutica Nv Anvendelse af NF-KB-inhibitorer til behandling af mastitis
US20050288253A1 (en) * 2002-09-09 2005-12-29 Trigen Limited Boronic acid salts
US20050119226A1 (en) * 2003-09-09 2005-06-02 Trigen Limited Methods for synthesizing organoboronic compounds and products thereof
KR20050057294A (ko) * 2002-09-09 2005-06-16 트라이젠 리미티드 보론산 염, 및 혈전증의 치료를 위한 그것의 용도
US20050176651A1 (en) * 2002-09-09 2005-08-11 Trigen Limited Peptide boronic acids useful in making salts thereof
US20050282757A1 (en) * 2002-09-09 2005-12-22 Trigen Limited Peptide boronic acid compounds useful in anticoagulation
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
EP1542768A1 (fr) * 2002-09-20 2005-06-22 Alcon, Inc. Utilisation d'inhibiteurs de la synthese des cytokines dans le traitement des troubles associes a la keratoconjonctivite seche
US20040156854A1 (en) 2002-12-06 2004-08-12 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
CN100341880C (zh) * 2003-02-13 2007-10-10 上海仁虎制药股份有限公司 新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
US20070110785A1 (en) * 2003-07-03 2007-05-17 Eugene Tedeschi Medical devices with proteasome inhibitors for the treatment of restenosis
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US20050112130A1 (en) * 2003-11-05 2005-05-26 Bhat Neelima M. Enhanced B cell cytotoxicity of CDIM binding antibody
US20060052390A1 (en) * 2003-12-24 2006-03-09 Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
AU2005216970B2 (en) * 2004-02-23 2011-07-07 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
AU2016202747B2 (en) * 2004-03-30 2017-11-23 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
EP2377868A1 (fr) * 2004-03-30 2011-10-19 Millennium Pharmaceuticals, Inc. Synthèse de Bortezomib
CA2562411A1 (fr) 2004-04-15 2005-11-10 Proteolix, Inc. Composes pour l'inhibition enzymatique
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP2030981B1 (fr) 2004-05-10 2014-07-09 Onyx Therapeutics, Inc. Composés pour l'inhibition d'une enzyme de proteasome
EP1765313A2 (fr) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Composes utilises pour l'immunopotentialisation
CN101087756B (zh) 2004-07-23 2011-04-06 纽阿达有限责任公司 肽酶抑制剂
EA010652B1 (ru) 2004-07-28 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы
WO2006045066A2 (fr) 2004-10-20 2006-04-27 Proteolix, Inc. Composes pour inhibition d'enzymes
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
KR20080007425A (ko) 2004-11-05 2008-01-21 팔링겐, 인코포레이티드 항체 유도된 세포막 손상
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
CA2595749A1 (fr) * 2005-01-27 2006-08-03 Research Development Foundation Therapie de combinaison avec des composes triterpenoides et des inhibiteurs de proteasome
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP2343304B1 (fr) 2005-02-16 2015-06-10 Anacor Pharmaceuticals, Inc. Composés boronophthalide biocides
WO2006099261A2 (fr) * 2005-03-11 2006-09-21 The University Of North Carolina At Chapel Hill Inhibiteurs puissants et spécifiques d'immunoprotéasomes
KR20080007642A (ko) * 2005-04-29 2008-01-22 코산 바이오사이언시즈, 인코포레이티드 프로테아좀 억제제와 함께 17-ａａｇ 또는 17-ａｇ 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법
DK1885710T3 (en) 2005-05-18 2015-11-23 Janssen Pharmaceutica Nv SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
SI1888123T1 (sl) * 2005-06-08 2013-04-30 Janssen Biotech, Inc. Celična terapija za okularno degeneracijo
US20090017006A1 (en) * 2005-07-06 2009-01-15 Biodevelops Pharma Entwicklung Gmbh Use of a compound for enhancing the expression of membrane proteins on the cell surface
US7531517B2 (en) 2005-08-10 2009-05-12 4Sc Ag Inhibitors of cancer cell, T-cell and keratinocyte proliferation
EP1752467A1 (fr) 2005-08-10 2007-02-14 4Sc Ag Inhibiteurs de la proliferation de cellules cancereuses, de cellules t, et de keratinocytes
US20070059382A1 (en) * 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
PT1948678E (pt) 2005-11-09 2013-07-16 Onyx Therapeutics Inc Compostos para inibição de enzimas
EP1956908A2 (fr) * 2005-12-08 2008-08-20 Cytokinetics, Inc. Compositions et procedes de traitement
WO2007078340A2 (fr) 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Petites molecules contenant du bore
JP5137848B2 (ja) * 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
WO2007082874A1 (fr) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Dérivés de pyridine et de pyrimidine en tant qu'inhibiteurs d'histone désacétylase
SI1981874T1 (sl) * 2006-01-19 2009-10-31 Janssen Pharmaceutica Nv Aminofenilni derivati kot novi inhibitorji histon deacetilaze
DK1981875T3 (da) * 2006-01-19 2014-07-14 Janssen Pharmaceutica Nv Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
EP1988779B1 (fr) * 2006-02-16 2015-06-24 Anacor Pharmaceuticals, Inc. Petites molecules contenant du bore en tant qu'agents anti-inflammatoires
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
CA2657213C (fr) 2006-06-19 2017-01-03 Proteolix, Inc. Peptides epoxycetones pour l'inhibition de proteasomes
BRPI0716838A2 (pt) * 2006-09-15 2013-10-01 Janssen Pharmaceutica Nv combinaÇÕes de inibidores de histona deacetilase especÍfica de classe i com inibidores de proteosome
CA2659070C (fr) * 2006-09-15 2014-10-21 Janssen Pharmaceutica Nv Inhibiteurs de l'histone desacetylase a activite combinee sur les histone desacetylases de classe i et de classe iib, combines a des inhibiteurs du proteasome
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
CA2606634A1 (fr) * 2006-12-08 2008-06-08 Centenary Institute Of Cancer Medicine And Cell Biology Essai biologique repondant aux effets des inhibiteurs du proteasome
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
RU2473685C2 (ru) 2007-07-31 2013-01-27 Лайфскен, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
JP2010535708A (ja) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
PL2178888T3 (pl) * 2007-08-06 2012-11-30 Millennium Pharm Inc Inhibitory proteasomów
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
JP2010539183A (ja) * 2007-09-12 2010-12-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ボルテゾミブおよびその生成のためのプロセス
US20090076031A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bortezomib
ES2578905T5 (es) 2007-10-04 2020-03-18 Onyx Therapeutics Inc Inhibidores de proteasa epoxi cetona peptídicos cristalinos y la síntesis de ceto-epóxidos de aminoácidos
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
CN101878298B (zh) 2007-11-27 2017-08-15 生命扫描有限公司 人胚胎干细胞的分化
CN101220048B (zh) * 2007-12-14 2012-08-15 江苏先声药物研究有限公司 ZnCl2催化下的蒎烷二醇酯的制备方法
PA8809001A1 (es) 2007-12-20 2009-07-23 Novartis Ag Compuestos organicos
CN105886459A (zh) 2008-02-21 2016-08-24 詹森生物科技公司 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物
BRPI0908565A2 (pt) * 2008-03-06 2017-05-23 Anacor Pharmaceuticals Inc composto, formulação farmacêutica, métodos para reduzir a liberação de uma citocina ou de uma quimiocina, para tratar uma condição em um animal e para inibir uma fosfodiesterase
WO2009140309A2 (fr) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
GEP201706703B (en) 2008-06-17 2017-07-25 Millennium Pharmaceuticals Inc (A Delaware Corporation) Boronate ester compounds and pharmaceutical compositions thereof
KR101829310B1 (ko) 2008-06-30 2018-02-14 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
CN101638414B (zh) * 2008-07-30 2014-01-08 江苏先声药物研究有限公司 肽硼酸及其酯类化合物、制备方法及其用途
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
EP2348863A4 (fr) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Petites molécules contenant du bore
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
AP2011005690A0 (en) 2008-10-21 2011-06-30 Onyx Therapeutics Inc Combination therapy with peptide epoxyketones.
ES2634445T3 (es) 2008-10-31 2017-09-27 Janssen Biotech, Inc. Diferenciación de las células madre embrionarias humanas con el linaje endocrino pancreático
EP2350265B1 (fr) * 2008-10-31 2019-04-17 Janssen Biotech, Inc. Différenciation de cellules souches embryonnaires humaines en la lignée endocrine pancréatique
US20100124781A1 (en) 2008-11-20 2010-05-20 Shelley Nelson Pluripotent Stem Cell Culture on Micro-Carriers
JP5719305B2 (ja) * 2008-11-20 2015-05-13 ヤンセン バイオテツク，インコーポレーテツド 平面支持体上での細胞付着及び培養のための方法及び組成物
CN101747354B (zh) * 2008-12-04 2014-08-13 江苏先声药物研究有限公司 一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
AU2009335744A1 (en) * 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy) -3H-benzo[c][1,2] oxaborol-1-ol
CA2748921A1 (fr) 2009-01-09 2010-08-12 Sun Pharma Advanced Research Company Limited Composition pharmaceutique
EP2399129B1 (fr) 2009-02-20 2015-11-25 Michael P. Lisanti Procédé de diagnostic ou de pronostic d'un néoplasme comprenant la détermination du taux d'expression d'une protéine dans des cellules stromales adjacentes au néoplasme
JP5709766B2 (ja) 2009-03-12 2015-04-30 ジェネンテック， インコーポレイテッド 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用
WO2010106135A1 (fr) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Utilisation combinée pour le traitement d'un carcinome ovarien
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US9605317B2 (en) 2009-03-24 2017-03-28 Janssen Pharmaceutica Nv Biomarkers for assessing peripheral neuropathy response to cancer treatment
WO2010114770A1 (fr) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-agent, particules, compositions et procédés d'utilisation apparentés
WO2010114768A1 (fr) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-épothilone, particules, compositions et procédés d'utilisation apparentés
CA2756072A1 (fr) * 2009-03-30 2010-10-14 Cerulean Pharma Inc. Conjugues polymere-agent, particules, compositions et procedes d'utilisation apparentes
CN102458127B (zh) * 2009-05-27 2014-08-27 赛福伦公司 用于治疗多发性骨髓瘤的联合治疗
CN101928329B (zh) * 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
EP2280016A1 (fr) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. Nouvelle voie de synthèse pour la préparation d'esters boroniques aminés via des Alk-1-ynes substitués
EP2270019A1 (fr) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. Nouvelle voie de synthèse pour la préparation d'esters boronique alpha-aminé
US9315525B2 (en) 2009-06-19 2016-04-19 Lek Pharmaceuticals D.D. Synthetic route for the preparation of α-amino boronic acid derivatives via substituted alk-1-ynes
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
DE102009027754A1 (de) 2009-07-15 2011-05-05 Schubert, Ulrich, Dr. Verfahren zur Hemmung der Reifung von dendritischen Zellen
CN102482640B (zh) * 2009-07-20 2015-03-11 詹森生物科技公司 人胚胎干细胞的分化
RU2579278C2 (ru) 2009-07-20 2016-04-10 Янссен Байотек, Инк. Популяция панкреатических эндокринных клеток-предшественников для снижения концентрации глюкозы в крови и способ дифференцировки панкреатических эндодермальных клеток
CN102597219B (zh) 2009-07-20 2015-08-19 詹森生物科技公司 人胚胎干细胞的分化
JP2013500974A (ja) * 2009-07-28 2013-01-10 アナコール ファーマシューティカルズ，インコーポレイテッド 三置換ホウ素含有分子
WO2011019618A1 (fr) * 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore et utilisables en tant qu'agents antiprotozoaires
US20120149663A1 (en) 2009-08-18 2012-06-14 Georgetown University Boronic acid compositions and methods related to cancer
WO2011022337A1 (fr) * 2009-08-19 2011-02-24 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore en tant qu'agents anti-protozoaires
JP5567136B2 (ja) 2009-09-08 2014-08-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ４−置換ピリジン−３−イル−カルボキサミド化合物及び使用方法
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
EP2305285A1 (fr) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Supports et procédés pour traiter les conditions ischémiques
HUE032571T2 (en) 2009-10-01 2017-09-28 Janssen Pharmaceutica Nv Proteasome inhibitors for cancer treatment
US9346834B2 (en) 2009-10-20 2016-05-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US8461134B2 (en) * 2009-11-11 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
CN102725300B (zh) * 2009-12-22 2015-03-11 赛福伦公司 蛋白酶体抑制剂及其制备、纯化、和应用的方法
EP2516626B1 (fr) 2009-12-23 2017-05-10 Janssen Biotech, Inc. Différenciation de cellules souches embryonnaires humaines
CA2784415C (fr) 2009-12-23 2019-06-18 Jean Xu Differenciation de cellules souches embryonnaires humaines
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011094450A1 (fr) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Petites molecules contenant du bore
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
CN102791851B (zh) 2010-03-01 2017-07-14 詹森生物科技公司 纯化衍生自多能干细胞的细胞的方法
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
US9061037B2 (en) * 2010-03-18 2015-06-23 Innopharma, Inc. Stable bortezomib formulations
AP2012006482A0 (en) 2010-03-19 2012-10-31 Anacor Pharmacueticals Inc Boron-containing small molecules as anti-protozoalagent
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
AU2013204868B2 (en) * 2010-03-31 2016-10-13 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US8513218B2 (en) * 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
WO2011136905A2 (fr) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Inhibiteur d'immunoprotéasome de peptide époxycétone cristallin
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
WO2011133479A2 (fr) 2010-04-19 2011-10-27 Niiki Pharma Inc. Polythérapie avec un inhibiteur du protéasome et un complexe de gallium
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
EP3498825A1 (fr) 2010-05-12 2019-06-19 Janssen Biotech, Inc. Différenciation de cellules souches embryonnaires humaines
CA2799202C (fr) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions et procedes de traitement de maladies auto-immunes et autres
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
CA2809305C (fr) 2010-08-31 2019-06-11 Janssen Biotech, Inc. Differenciation de cellules souches pluripotentes
BR112013004514A2 (pt) 2010-08-31 2016-06-07 Janssen Biotech Inc diferenciação das células-tronco embrionárias humanas
SG10201506855RA (en) 2010-08-31 2015-10-29 Janssen Biotech Inc Differentiation of human embryonic stem cells
MX338209B (es) 2010-09-07 2016-04-07 Anacor Pharmaceuticals Inc Derivados de benzoxaborol para tratar infecciones bacterianas.
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
EP2624818B1 (fr) 2010-10-05 2017-04-05 Fresenius Kabi USA, LLC Formulations de bortézomib stabilisées par de l'acide borique
EP2627636B1 (fr) 2010-10-14 2015-09-02 Synthon BV Procédé pour la fabrication de bortézomib et des intermédiaires pour la procédé
PE20140293A1 (es) 2011-01-31 2014-03-19 Novartis Ag Novedosos derivados heterociclicos
TW201309303A (zh) * 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
US9272014B2 (en) 2011-03-29 2016-03-01 Texas Tech University System Galectin-3C combination therapy for human cancer
MX348798B (es) 2011-03-31 2017-06-29 Nanocarrier Co Ltd Composicion farmaceutica que contiene copolimero en bloque que comprende compuesto de acido boronico.
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
WO2012177835A1 (fr) * 2011-06-22 2012-12-27 Cephalon, Inc. Inhibiteurs du protéasome et leurs méthodes de préparation, de purification et d'utilisation
US8481655B2 (en) 2011-07-27 2013-07-09 Wacker Chemical Corporation Copper complexes of amino-functional organosilicon compounds and their use
WO2013021032A1 (fr) 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Inhibiteurs d'histone désacétylase en combinaison avec des inhibiteurs du protéasome et la dexaméthasone
US9322066B2 (en) 2011-08-11 2016-04-26 Janssen Pharmaceutica Nv Predictors for cancer treatment
WO2013028371A1 (fr) 2011-08-19 2013-02-28 Glaxo Group Limited Composés benzofuranes pour le traitement d'infections par le virus de l'hépatite c
HUE060305T2 (hu) * 2011-08-30 2023-02-28 Tufts College FAP-aktivált proteaszóma inhibitorok a szolid tumorok kezelésére
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2771342B1 (fr) 2011-10-28 2016-05-18 Novartis AG Dérivés de purine et utilisation de ceux-ci dans le traitement d'une maladie
WO2013063496A1 (fr) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarqueurs de réponse aux inhibiteurs de nae
CN104039328B (zh) 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
US20150184246A1 (en) 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013073697A1 (fr) 2011-11-17 2013-05-23 国立大学法人 東京大学 Copolymère séquencé dans lequel un groupe acide phénylboronique a été introduit, et utilisation de ce dernier
RU2705001C2 (ru) 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
WO2013110005A1 (fr) 2012-01-18 2013-07-25 Wisconsin Alumni Research Foundation Administration de médicament médiée par les boronate
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
US20160008382A1 (en) 2012-01-24 2016-01-14 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
WO2013120012A2 (fr) 2012-02-08 2013-08-15 Igm Biosciences Inc. Protéines se liant aux cdim et leurs utilisations
US10293048B2 (en) 2012-03-02 2019-05-21 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
EP2823037A4 (fr) 2012-03-07 2015-09-16 Janssen Biotech Inc Milieux définis pour le développement et la préservation des cellules souches pluripotentes
CA2784240C (fr) 2012-03-27 2014-07-08 Innopharma, Inc. Formulations stables a base de bortezomib
AU2013263043B2 (en) 2012-05-16 2016-06-16 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
AU2013271581B2 (en) 2012-06-08 2018-08-09 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
EP2679596B1 (fr) 2012-06-27 2017-04-12 International Aids Vaccine Initiative Variante de la protéine env du VIH-1
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
JP2013006855A (ja) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc プロテアソーム阻害剤
KR20150067175A (ko) * 2012-09-11 2015-06-17 시플라 리미티드 보르테조밉을 제조하기 위한 방법
CN104822844B (zh) 2012-10-01 2019-05-07 米伦纽姆医药公司 预测对抑制剂的反应的生物标记物和方法以及其用途
WO2014072985A1 (fr) 2012-11-06 2014-05-15 Natco Pharma Limited Nouveaux dérivés d'acide boronique an tant qu'agents anticancéreux
CA2891822A1 (fr) 2012-11-16 2014-05-22 Shilpa Medicare Limited Procede de preparation de bortezomib cristallin
WO2014097306A1 (fr) 2012-12-21 2014-06-26 Natco Pharma Limited Forme polymorphe stable et pure du bortézomib
WO2014105543A1 (fr) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Culture de cellules souches embryonnaires humaines à l'interface air-liquide en vue de la différenciation en cellules endocrines pancréatiques
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
CA2896750A1 (fr) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Mise en suspension et agregation de cellules pluripotentes humaines pour la differenciation en cellules endocrines du pancreas
BR112015015701A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc diferenciação de células-tronco embrionárias humanas em células pancreáticas endócrinas com o uso de reguladores hb9
DK2968316T3 (da) 2013-03-13 2019-10-07 Forma Therapeutics Inc 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-on-derivater og relaterede forbindelser som fedtsyresyntase (fasn)-inhibitorer til behandlingen af cancer
IN2013MU01431A (fr) 2013-04-16 2015-06-26 Cipla Ltd
WO2014172627A1 (fr) 2013-04-19 2014-10-23 Thomas Jefferson University Methodes associees a la caveoline-1 pour le traitement d'un glioblastome par temozolomide
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2015003146A1 (fr) 2013-07-03 2015-01-08 Georgetown University Dérivés acide boronique de resvératrol pour l'activation des enzymes désacétylases
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EA201690686A1 (ru) 2013-10-03 2016-08-31 Милленниум Фармасьютикалз, Инк. Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN104586776B (zh) * 2013-10-30 2017-05-17 扬子江药业集团上海海尼药业有限公司 以硼替佐米为活性成分的制剂及其制备方法
JP6468562B2 (ja) * 2013-11-21 2019-02-13 国立大学法人北海道大学 プロテアソーム阻害性化合物
WO2015085097A1 (fr) * 2013-12-05 2015-06-11 The Broad Institute, Inc. Compositions et méthodes pour identifier et traiter la cachexie ou la pré-cachexie
TN2016000179A1 (en) 2013-12-06 2017-10-06 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
US10167311B2 (en) 2014-02-03 2019-01-01 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
EP2910557A1 (fr) * 2014-02-20 2015-08-26 Ikerchem, S.L. Pyrrolidines tétrasubstitués énantiopures en tant qu'échafaudages pour inhibiteurs de protéasome et ses applications médicinales
JP6566936B2 (ja) 2014-05-08 2019-08-28 国立大学法人 東京大学 医薬組成物
DK3143127T3 (da) 2014-05-16 2021-09-13 Janssen Biotech Inc Anvendelse af små molekyler til at forstærke mafa-ekspression i endokrine pankreasceller
MA39964A (fr) 2014-05-20 2015-11-26 Millennium Pharm Inc Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire
EP3808349B1 (fr) 2014-08-07 2022-10-05 Mayo Foundation for Medical Education and Research Composés et procédés pour le traitement du cancer
EP3201208B1 (fr) * 2014-10-01 2021-03-24 Merck Patent GmbH Dérivés d'acide boronique
WO2016110870A1 (fr) 2015-01-07 2016-07-14 Emcure Pharmaceuticals Limited Composition pharmaceutique de bortézomid
MA41505A (fr) 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
JP2018510859A (ja) 2015-03-17 2018-04-19 レオン−ナノドラッグズ ゲーエムベーハー 安定化されたボロン酸化合物を含むナノ粒子
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
WO2016184793A1 (fr) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de traitement de patients souffrant d'un adénocarcinome rénal métastatique résistant aux inhibiteurs du vegfr
US10144761B2 (en) 2015-06-19 2018-12-04 Hanlin Scientific Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
EP3120837A1 (fr) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Solution de bortezomib prêts à l'emploi
EP3120836A1 (fr) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Solution de bortezomib prêts à l'emploi
CN106478700B (zh) * 2015-08-26 2020-12-29 杭州雷索药业有限公司 硼基取代的苯胺类蛋白激酶抑制剂
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
WO2017106196A1 (fr) 2015-12-14 2017-06-22 The Broad Institute, Inc. Compositions et procédés de traitement des dysfonctionnements cardiaques
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途
CN107151254A (zh) * 2016-03-06 2017-09-12 复旦大学 一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CN106008572B (zh) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 一类二肽硼酸化合物及制备方法和用途
KR102595723B1 (ko) 2016-06-21 2023-10-27 오리온 옵탈몰로지 엘엘씨 헤테로시클릭 프롤린아미드 유도체
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
JP6681284B2 (ja) * 2016-06-23 2020-04-15 信越化学工業株式会社 糖アルコール化合物の金属低減方法
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018038687A1 (fr) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Formulations pharmaceutiques comprenant un complexe bortézomib-cyclodextrine
WO2018060833A1 (fr) 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
CA3040820A1 (fr) 2016-10-20 2018-04-26 Pfizer Inc. Particules therapeutiques avec des composes peptidiques d'acide boronique ou d'ester de boronate et leurs procedes de fabrication et d'utilisation
WO2018129533A1 (fr) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Inhibiteurs sélectifs d'histone déacétylase pour le traitement d'une maladie humaine
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
AU2018221670B2 (en) 2017-02-17 2021-02-04 Fresenius Kabi Oncology Ltd. An improved process for the preparation of boronic acid esters
WO2018160717A1 (fr) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Composés et méthodes de traitement du cancer
JP7289828B2 (ja) 2017-08-23 2023-06-12 ケザール ライフ サイエンシズ 自己免疫疾患の治療における免疫プロテアソーム阻害剤および免疫抑制剤
EP3694878A1 (fr) 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Polythérapie pour le traitement du cancer
JP2018024694A (ja) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
MX2020005046A (es) 2017-11-16 2020-08-20 Principia Biopharma Inc Inhibidores de inmunoproteasoma.
MX2020005036A (es) * 2017-11-16 2020-08-17 Principia Biopharma Inc Inhibidores de inmunoproteasoma.
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US20210106522A1 (en) 2018-01-29 2021-04-15 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
TW202003553A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療癌症之abbv-621與抗癌劑之組合
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN109824756B (zh) * 2019-03-19 2022-03-22 山东大学 含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
CN114437119A (zh) * 2020-10-30 2022-05-06 苏州开拓药业股份有限公司 一种c-Myc蛋白抑制剂及其制备方法和用途
EP4255920A2 (fr) * 2020-12-02 2023-10-11 Hoffman Technologies LLC Compositions et méthodes de modulation d'un cancer chez des mammifères non humains
TW202237143A (zh) * 2020-12-10 2022-10-01 南韓商Ｌｇ化學股份有限公司 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
US20230062279A1 (en) 2021-08-12 2023-03-02 Extrovis Ag Pharmaceutical compositions of bortezomib
CN113957441B (zh) * 2021-10-29 2024-01-02 光华科学技术研究院(广东)有限公司 蚀刻液及其制备方法和应用
WO2023220655A1 (fr) 2022-05-11 2023-11-16 Celgene Corporation Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
WO2023220641A2 (fr) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Méthodes et utilisations associées à une thérapie par lymphocytes t et leur production
WO2024097905A1 (fr) 2022-11-02 2024-05-10 Celgene Corporation Méthodes de traitement au moyen d'une thérapie par lymphocytes t et d'une thérapie d'entretien par agent immunomodulateur

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261868A (en) * 1979-08-08 1981-04-14 Lever Brothers Company Stabilized enzymatic liquid detergent composition containing a polyalkanolamine and a boron compound
US4369183A (en) * 1979-09-06 1983-01-18 Merck & Co., Inc. 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
US4510130A (en) 1983-05-20 1985-04-09 Genetic Diagnostics Corporation Promoting animal and plant growth with leupeptin
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4537707A (en) * 1984-05-14 1985-08-27 The Procter & Gamble Company Liquid detergents containing boric acid and formate to stabilize enzymes
US4842769A (en) * 1985-07-26 1989-06-27 Colgate-Palmolive Co. Stabilized fabric softening built detergent composition containing enzymes
US4759032A (en) 1987-06-03 1988-07-19 Monsanto Company Electrode seal assembly
US5250720A (en) * 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
SE8702550D0 (sv) * 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
ATE108185T1 (de) 1987-06-19 1994-07-15 Univ California Neue klasse von niedrigkalorischen proteinsüssstoffen.
EP0315574A3 (fr) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Inhibiteurs de la rénine
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US4963655A (en) * 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US4959179A (en) * 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
US5030378A (en) * 1990-01-02 1991-07-09 The Procter & Gamble Company Liquid detergents containing anionic surfactant, builder and proteolytic enzyme
IE910713A1 (en) 1990-03-05 1991-09-11 Cephalon Inc Chymotrypsin-like proteases
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
EP0478050A1 (fr) * 1990-09-24 1992-04-01 Unilever N.V. Composition détergente
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
AU667463B2 (en) * 1990-12-28 1996-03-28 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
CZ230593A3 (en) * 1991-04-30 1994-04-13 Procter & Gamble Liquid detergents with arylboric acid
ATE136055T1 (de) * 1991-04-30 1996-04-15 Procter & Gamble Gerüstsubstanzhaltige flüssigwaschmittel mit borsäure-polyolkomplex zur ptoteolytischen enzyminhibierung
EP0511456A1 (fr) * 1991-04-30 1992-11-04 The Procter & Gamble Company Détergents liquides contenant un ester aromatique de l'acide borique pour inhibition d'enzyme protéolitique
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
CA2133658A1 (fr) * 1992-04-16 1993-10-28 Peter R. Bernstein Derives heterocycliques
DE69314169T2 (de) * 1992-04-16 1998-01-15 Zeneca Ltd Peptide mit eine alphaaminoboronaire gruppe and ihre verwendung als elastasehemmer
ATE149563T1 (de) 1992-08-14 1997-03-15 Procter & Gamble Alpha-aminoborsäurehaltige flüssige waschmittel
JPH08507754A (ja) 1993-02-10 1996-08-20 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ Ｍｈｃ−１拘束性抗原提示におけるａｔｐ−ユビキチン依存蛋白分解の役割およびそのインヒビター
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
DE4311835A1 (de) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
US5424904A (en) * 1993-10-04 1995-06-13 Taylor, Sr.; Thomas T. Circuit for electrically controlled intermittent motion
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5550262A (en) * 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
EP1355910B1 (fr) * 2001-01-25 2011-03-09 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation de composes d'acide boronique
EP2377868A1 (fr) * 2004-03-30 2011-10-19 Millennium Pharmaceuticals, Inc. Synthèse de Bortezomib

Also Published As

Publication number Publication date
NO971929L (no) 1997-06-12
US20060122390A1 (en) 2006-06-08
JP3717934B2 (ja) 2005-11-16
AU4139896A (en) 1996-05-23
EP1627880A1 (fr) 2006-02-22
TW318850B (fr) 1997-11-01
CY2484B1 (en) 2005-06-03
KR100398944B1 (ko) 2004-06-04
US7119080B2 (en) 2006-10-10
DE69530936T3 (de) 2010-08-26
US6465433B1 (en) 2002-10-15
IL133831A (en) 2004-03-28
EP0788360A1 (fr) 1997-08-13
US20020173488A1 (en) 2002-11-21
US20070282100A1 (en) 2007-12-06
DE69534727D1 (de) 2006-02-02
DK0788360T3 (da) 2003-09-22
US20150072942A1 (en) 2015-03-12
ATE411324T1 (de) 2008-10-15
EP0788360B1 (fr) 2003-05-28
ES2254803T3 (es) 2006-06-16
EP1312609B1 (fr) 2005-12-28
PT1627880E (pt) 2009-01-23
NO310558B1 (no) 2001-07-23
US20040167332A1 (en) 2004-08-26
NO971929D0 (no) 1997-04-25
FR04C0014I1 (fr) 2004-09-17
JPH10510245A (ja) 1998-10-06
US20110306560A1 (en) 2011-12-15
US20080132678A1 (en) 2008-06-05
US20130310320A1 (en) 2013-11-21
DK1627880T3 (da) 2008-12-08
DE69530936D1 (de) 2003-07-03
LU91083I2 (fr) 2004-08-09
ES2199257T7 (es) 2010-03-31
CA2496538A1 (fr) 1996-05-09
ES2199257T3 (es) 2004-02-16
NL300151I1 (nl) 2004-08-02
IL115790A0 (en) 1996-01-19
FI114801B (fi) 2004-12-31
WO1996013266A1 (fr) 1996-05-09
US6297217B1 (en) 2001-10-02
CN1168633A (zh) 1997-12-24
CN1305475C (zh) 2007-03-21
FI971746A (fi) 1997-06-06
EP1627880B1 (fr) 2008-10-15
CN101077875A (zh) 2007-11-28
CN101077875B (zh) 2011-01-26
EP1312609A1 (fr) 2003-05-21
US6617317B1 (en) 2003-09-09
CH0788360H1 (de) 2006-03-15
NZ296717A (en) 1999-11-29
HK1002059A1 (en) 1998-07-31
IL133831A0 (en) 2001-04-30
US6548668B2 (en) 2003-04-15
DE122004000025I2 (de) 2006-09-07
US20030199561A1 (en) 2003-10-23
DK0788360T5 (da) 2017-09-18
FI971746A0 (fi) 1997-04-23
PT788360E (pt) 2003-10-31
FI20041415A (fi) 2004-11-03
CA2203936A1 (fr) 1996-05-09
US6083903A (en) 2000-07-04
US20090247731A1 (en) 2009-10-01
EP0788360B3 (fr) 2009-08-12
NL300151I2 (nl) 2004-09-01
CA2203936C (fr) 2005-04-12
MX9703063A (es) 1998-07-31
US7531526B2 (en) 2009-05-12
NO2004004I1 (no) 2004-08-06
PT1312609E (pt) 2006-05-31
NZ337211A (en) 2000-12-22
KR970706824A (ko) 1997-12-01
US6066730A (en) 2000-05-23
AU710564B2 (en) 1999-09-23
US6747150B2 (en) 2004-06-08
DE69530936C5 (de) 2007-02-22
AU710564C (en) 1996-05-23
DK1312609T3 (da) 2006-05-15
HK1087714A1 (en) 2006-10-20
EP1997823A1 (fr) 2008-12-03
FI120974B (fi) 2010-05-31
US5780454A (en) 1998-07-14
NO2004004I2 (no) 2007-09-10
IL115790A (en) 2002-12-01
ES2314540T3 (es) 2009-03-16
DE69535866D1 (de) 2008-11-27
ATE241631T1 (de) 2003-06-15
CA2496538C (fr) 2011-08-02
DE69530936T2 (de) 2004-02-26
IL137726A0 (en) 2001-10-31
FR04C0014I2 (fr) 2005-05-21
DE122004000025I1 (de) 2004-09-30
IL137726A (en) 2004-08-31
US8378099B2 (en) 2013-02-19
DE69534727T2 (de) 2006-09-14
EP0788360A4 (fr) 1998-05-06
ATE314378T1 (de) 2006-01-15
US8003791B2 (en) 2011-08-23

Similar Documents

Publication Publication Date Title
FR04C0014I2 (fr)
ZA9610687B (en) Novel synthesis.
ZA965505B (en) Novel compounds.
ZA957726B (en) 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives
EP0737314A4 (fr) Nouvelles utilisations de produits de recombinaison de recepteurs de gal4
HU9400745D0 (en) 2,4-diamino-3-hydroxy-carboxylic acid derivatives
ZA966396B (en) Boronic acid derivatives.
ZA942880B (en) 2,6.disubstituted 4-quinolyl-dihydropridines
AU2618995A (en) Novel 3,5-dimethylpiperidin-1-ylalkyl esters
ZA965504B (en) Novel compounds.
ZA968757B (en) Novel formulations.
ZA941734B (en) 2,4-diamino-3-hydroxycarboxylic acid derivatives
ZA975696B (en) Novel compounds.
ZA97415B (en) Novel compounds.
GB9326343D0 (en) Novel catalyst composition